课题基金 / 基金详情

Protocolized Care for Early Septic Shock (ProCESS)

Protocolized Care for Early Septic Shock (ProCESS)
早期感染性休克的规范化护理 (ProCESS)
批准号:
7938400
负责人:
Derek C Angus
金额:
$231.5万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-30 至 2012-08-31

项目摘要

项目成果

Derek C Angus的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Severe sepsis is the syndrome of acute organ dysfunction secondary to infection. It affects 750,000 Americans each year, with a mortality of 30%. Despite considerable understanding of the pathophysiology of sepsis, current efforts to improve care are hampered by limited empiric data regarding the amount and timing of sepsis therapies. This stands in stark contrast to other acute conditions, such as acute coronary syndromes, where standardized, prompt, rigorous care has led to a large improvement in outcome and paved the way for better clinical and translational research. We have amassed for this Center proposal a multidisciplinary group of investigators and consortium of leading institutions. Our goal is to address the overarching hypothesis that there are 'golden hours' in the initial management of sepsis and septic shock where prompt, rigorous, standardized care can reduce unwanted downstream consequences and improve clinical outcomes. Our efforts capitalize on the findings of a recent 'proof-of-concept' trial by Rivers et al. They demonstrated in a single center randomized trial that 6 h of protocolized resuscitation for subjects presenting to the Emergency Department (ED) with early septic shock dramatically improved mortality when compared to usual care. While this study was revolutionary, it left unanswered whether the findings are generalizable and whether all elements of the protocol are necessary, especially the use of central venous catheterization and blood transfusion. The apparent success of the Rivers protocol also prompts questions about the mechanisms by which resuscitation techniques affect outcome. And, there are important questions regarding the logistic and economic constraints to widespread implementation of protocolized resuscitation across the US. We will tackle these questions directly through execution of a large multicenter trial. We will randomize 1950 subjects who present to the ED in septic shock to 3 arms (650/arm): the 'Rivers' protocol; a simpler, less invasive protocol (using esophageal Doppler monitoring and no blood transfusion); and usual care. Protocols will be implemented using best evidence regarding guideline dissemination. We have organized our efforts under 3 integrated subprojects. Subproject #1 (Clinical Efficacy) will conduct the trial and test whether protocolized care improves mortality compared to usual care and whether the full Rivers protocol is necessary. Subproject #2 (Mechanisms of Action) will measure concentrations over time of carefully selected circulating markers of four fundamental pathways implicated in sepsis-related organ dysfunction (cellular hypoxia, oxidative stress, inflammation, and coagulation/thrombosis) and test whether protocolized resuscitation reduces expression of these markers and whether the clinical efficacy of these protocols is associated with reduced expression of these markers. Subproject #3 (Costs and Cost-effectiveness) will measure the incremental costs and resource use of protocolized resuscitation and determine the value, or cost-effectiveness, of the alternative strategies. These subprojects are supported by 3 cores: administration, human subjects, and data management and analysis. This project will generate new, important, and comprehensive data on the clinical, biologic, and pragmatic aspects of standard, prompt, rigorous resuscitation for septic shock. Our findings will aid scientists, clinicians, families and policymakers and will immediately affect care of the critically ill. As the number of Americans dying with sepsis is similar tothat of acute myocardial infarction, the proposed study has enormous implications for the public health of the country and is consistent with the recent NIH emphasis on translational research'(nihroadmap.nih.gov).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Precision Medicine Approach to Glucocortisteroids in Sepsis
Precision Medicine Approach to Glucocortisteroids in Sepsis
Preventive and Early Treatment of Acute Lung Injury Clinical Trials Network- Pgh
Preventive and Early Treatment of Acute Lung Injury Clinical Trials Network- Pgh
国内基金
海外基金
基于CARE解码框架的跨范式肌电无声语音识别新方法
  • 批准号:
    2026JJ70025
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    谭欣
  • 依托单位:
CarE06介导朱砂叶螨对甲氰菊酯对映体代谢抗性形成差异机制
  • 批准号:
    CSTB2023NSCQ-MSX0916
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2023
  • 负责人:
    张平
  • 依托单位:
棉铃虫羧酸酯酶CarE001G在杀虫剂代谢和抗性中的作用及机制
  • 批准号:
    U1903111
  • 项目类别:
    联合基金项目
  • 资助金额:
    57万元
  • 批准年份:
    2019
  • 负责人:
    李永强
  • 依托单位:
棉铃虫羧酸酯酶CarE001C定向进化及突变酶的结构与功能研究
  • 批准号:
    31201517
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    23.0万元
  • 批准年份:
    2012
  • 负责人:
    李永强
  • 依托单位: